People with Myotonic Dystrophy Type 1 (DM1), the most common adult-onset form of muscular dystrophy, progressively lose muscle mass and strength in their lower legs, hands, neck and face. The effects ...
US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...
A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1—the most prevalent form of adult-onset muscular dystrophy—provides insight into why patients develop fatty liver ...
Dyne Therapeutics, Inc. ( (DYN) ) has released its Q3 earnings. Here is a breakdown of the information Dyne Therapeutics, Inc. presented to its ...
"Myotonic Dystrophy Type 1 is an aggressive and challenging neuromuscular disorder affecting not only adults, but also children and has no approved treatment option for any age group," said Judith ...
Investor's Business Daily on MSN28d
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats UpThe three-horse race to treat a devastating form of muscular dystrophy is now down to two. One of the key players, Avidity ...
Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on PepGen Inc. (PEPG – Research Report), with a price target of ...
Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback